Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | EZH2 | Q15910 | 11/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649008 | 0.90 | EZH2 (0.49) | GLAKMT2AMEN1EZH2L3MBTL1 | |
| SCHEMBL5652674 | 0.90 | L3MBTL1 (0.52) | GLAKMT2AMEN1EZH2L3MBTL1 | |
| SCHEMBL5654366 | 0.89 | MEN1 (0.60) | GLAKMT2AMEN1EZH2L3MBTL1 | |
| SCHEMBL5651181 | 0.88 | EZH2 (0.55) | GLAKMT2AMEN1EZH2L3MBTL1 | |
| SCHEMBL5651443 | 0.87 | EZH2 (0.57) | GLAKMT2AMEN1EZH2L3MBTL1 | |
| SCHEMBL5653316 | 0.86 | EZH2 (0.48) | GLAKMT2AMEN1EZH2L3MBTL1 | |
| SCHEMBL5654560 | 0.85 | MEN1 (0.56) | GLAKMT2AMEN1EZH2L3MBTL1 | |
| SCHEMBL5654568 | 0.85 | MEN1 (0.56) | GLAKMT2AMEN1EZH2L3MBTL1 | |
| SCHEMBL5649687 | 0.84 | GLA (0.57) | GLAKMT2AMEN1EZH2L3MBTL1 | |
| SCHEMBL5649693 | 0.84 | GLA (0.57) | GLAKMT2AMEN1EZH2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | GLA 1633/4885KMT2A 439/4885MEN1 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.